CLINICAL TRIALS PROFILE FOR ANDROID-F

All Clinical Trials for ANDROID-F

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	Stanford University	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	University of Alabama at Birmingham	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02897934 ↗	CWI and Discharge After Breast Cancer Surgery	Completed	University College Cork		2016-08-01	The objectives of this work are threefold: 1. To evaluate the analgesic efficacy of CWI in women discharged within 23 hours of major breast cancer surgery 2. To evaluate objective indices of patient recovery following anaesthesia and surgery in a 23 hour model of care 3. To evaluate patient satisfaction with their care pathway
NCT03387787 ↗	Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2	Completed	University Hospital Inselspital, Berne	Phase 2/Phase 3	2018-01-30	The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. The GlucoTab® system was found capable to keep hospitalized diabetic patients in the recommended target range without increasing the risk for hypoglycaemic events. Insulin pharmacokinetic is a critical confounder of glycaemic variability and the main determinant of an algorithm-based decision support-system. GlucoTab® is intended for being used with a basal/bolus insulin regimen. Up to date, feasibility data are limited to the use of insulin glargine. Insulin degludec, an ultra-long acting basal insulin is characterized by a stable pharmacokinetic profile a half-life of ~25 hours. It was found equally effective to insulin glargine with respect to glycaemic control, while the incidence of (nocturnal) hypoglycaemia was smaller in patients treated with insulin degludec. Within the present study, insulin glargine will be replaced by insulin degludec, which is not yet approved for dose titration with GlucoTab®. In the present study, 15 non-critically ill T2DM patients, who were hospitalized at the University Clinic of Neurosurgery for various reasons and require insulin treatment will be recruited. Patients will be treated with insulin Tresiba and insulin Novorapid. For a maximum duration of 21 days, GlucoTab® will calculate the required insulin doses for each patient, depending on fasting plasma glucose and postprandial glucose measurements during the day. After the calculated Insulin dose has been approved by the physician, the nursing staff will give the dose to the respective patient. The present study will analyse the efficacy of GlucoTab® for glycaemic management in T2DM patients using insulin degludec.

Clinical Trial Conditions for ANDROID-F

Condition Name

Condition Name for ANDROID-F
Intervention	Trials
Breast Cancer	2
Tonsillar Bleeding	1
Leukemia	1
Type 2 Diabetes Mellitus	1

Condition MeSH

Condition MeSH for ANDROID-F
Intervention	Trials
Diabetes Mellitus	3
Postoperative Hemorrhage	1
Pain, Postoperative	1
Renal Insufficiency	1

Clinical Trial Locations for ANDROID-F

Trials by Country

Trials by Country for ANDROID-F
Location	Trials
Canada	4
United States	3
Switzerland	2
Ireland	1

Trials by US State

Trials by US State for ANDROID-F
Location	Trials
Vermont	1
Pennsylvania	1
California	1

Clinical Trial Progress for ANDROID-F

Clinical Trial Phase

Clinical Trial Phase for ANDROID-F
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ANDROID-F
Clinical Trial Phase	Trials
Completed	3
Recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for ANDROID-F

Sponsor Name

Sponsor Name for ANDROID-F
Sponsor	Trials
Stanford University	2
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	1
University of Calgary	1

Sponsor Type

Sponsor Type for ANDROID-F
Sponsor	Trials
Other	18

Clinical Trials Update, Market Analysis and 2026–2036 Projection for ANDROID-F

Last updated: June 11, 2026

No reliable, citable public information is available to identify “ANDROID-F” as a specific active ingredient, finished drug product, sponsor, trial registry entry, or marketed product. Without an unambiguous drug identity, trial listings, FDA regulatory status, patent landscape, and market data cannot be accurately compiled or projected.

H2: What is ANDROID-F (active ingredient) and who is developing it?
H3: Is ANDROID-F a branded drug, investigational compound, or code name?
No verifiable linkage to a specific development program is available from citable public sources under the name “ANDROID-F,” so sponsor, target, modality, and indication cannot be established for market or trials analysis.

H2: What clinical trials are registered for ANDROID-F and what are the latest readouts?
H3: Which registries show ANDROID-F (ClinicalTrials.gov, EU CTR, ISRCTN)?
No citable trial registry entries can be matched to “ANDROID-F” with sufficient specificity to extract phase, enrollment, endpoints, or timelines.

H2: What phase is ANDROID-F in and when are key milestones expected?
H3: Phase transition and expected completion dates
Because ANDROID-F cannot be uniquely identified, phase, recruitment status, interim analysis dates, and estimated study completion cannot be determined.

H2: What does the ANDROID-F efficacy and safety profile look like from published data?
H3: PubMed, conference abstracts, and company releases
No citable publications or conference disclosures can be attributed to ANDROID-F with enough specificity to summarize efficacy endpoints, adverse events, or dose-response.

H2: What is the competitive landscape for ANDROID-F in its therapeutic area?
H3: Who are the leading drugs and late-stage candidates?
The therapeutic area is not identifiable for ANDROID-F from citable sources, so competitor mapping cannot be performed.

H2: What is the current market size and TAM/SAM/SOM for ANDROID-F?
H3: Pricing assumptions and eligible patient models
No indication, active ingredient, route, or geography can be confirmed for ANDROID-F, so pricing and patient-model construction cannot be validated.

H2: When does ANDROID-F launch, and what adoption curve should be expected?
H3: Uptake drivers (mechanism, endpoints, guideline placement)
Launch timing and adoption drivers depend on the specific program identity, which is not verifiable.

H2: What are the regulatory and FDA pathway risks for ANDROID-F?
H3: NDA/BLA status, orphan, fast track, and exclusivity
No citable FDA regulatory record can be matched to ANDROID-F, so pathway classification and exclusivity implications cannot be stated.

H2: What patents protect ANDROID-F and what generic or biosimilar entry risks exist?
H3: Orange Book / Purple Book listings and Paragraph IV exposure
No active ingredient or applicant can be confirmed, so patent estate coverage and generic risk cannot be analyzed.

H2: What is the likely revenue projection for ANDROID-F from 2026 to 2036?
H3: Base case, upside, and downside scenarios
A projection requires validated inputs: indication, dose, duration, target population, pricing, and uptake timing. None are available for a uniquely identified ANDROID-F.

---

Key Takeaways

• ANDROID-F cannot be uniquely identified from citable public sources as a specific drug, active ingredient, sponsor program, or FDA-regulated product.
• Clinical trial updates, regulatory status, competitive benchmarking, and market/revenue projections cannot be produced without a validated drug identity.

---

FAQs

1. How can ANDROID-F be matched to the correct ClinicalTrials.gov entry if only the code name is known?
2. What FDA pathway signals (Fast Track, Breakthrough, RMAT) usually precede first NDA/BLA submission?
3. How do mechanism of action and comparators determine the adoption curve for oncology versus immunology drugs?
4. What drives geographic scaling of drug revenues (reimbursement vs tendering vs formulary access)?
5. How do patent expirations and exclusivity stacking change generic entry timelines?

---

References

No sources are cited because ANDROID-F cannot be tied to a verifiable drug identity for analysis.